NEW PAPER about ATH434 and endothelial cells !!!!, page-9

Johnmartin, I do not know they need to know anything more than we because even we know that ATH will make some money with PBT2 in the antibiotic resistance business. There are some 700.000 lives and billions of money to be saved by PBT2. But the problem is the fact that Alterity has not told us any news of PBT2 business development. I would say that we have lost the trust, that there will be PBT2 business ever because SP is very low.

That kind of a possibility that PBT2 most likely offers (according to the scientific reports about PBT2), cannot be ignored by any serious investor. For daytraders, it is almost worthless IMO. But they do not invest 17 million. Now the daytraders and perhaps robinhooders are in charge of SP, not the real serious investors. With high volatility and low market capital, this stock is a good playground for daytraders.

So I still trust the PBT2, but of course, I would like to get info on where are we today.

I am not an investment advisor, do your own research. But this is how I explain the low SP to myself. I may be wrong in my thoughts.